Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.

ABSTRACT: Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.

SUBMITTER: Fulcher JA 

PROVIDER: S-EPMC6093998 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature